<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874989</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00037000</org_study_id>
    <nct_id>NCT02874989</nct_id>
  </id_info>
  <brief_title>Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial</brief_title>
  <acronym>IPF</acronym>
  <official_title>Targeted Removal of Pro-Inflammatory Cells: An Open Label Human Pilot Study in Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study team hypothesizes that intermittent (3 doses administered over 3 consecutive days
      in 3 consecutive weeks) oral administration of combination Dasatinib (100 mg/d) + Quercetin
      (1250 mg/d) will be safe and well tolerated in patients with IPF. Treatment with D+Q will
      result in reduced abundance of pro-inflammatory cells within subjects over baseline. Finally,
      the reduction in biomarkers of cellular pro-inflammatory state will be related to no change
      in functional and patient reported outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 16, 2016</start_date>
  <completion_date type="Actual">June 3, 2019</completion_date>
  <primary_completion_date type="Actual">June 3, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Some patients will be randomized either to placebo or study drug and other patients will go into open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of pro-inflammatory expressing cells</measure>
    <time_frame>baseline</time_frame>
    <description>A skin biopsy will be obtained at baseline and the percentage of pro-inflammatory expressing cells will be recorded</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of pro-inflammatory expressing cells</measure>
    <time_frame>4 weeks post baseline visit biopsy/ 5 days post last dose study drug</time_frame>
    <description>A skin biopsy will be obtained at 4 weeks post baseline/5 days after the last dose of study medication and the percentage of pro-inflammatory expressing cells will be recorded</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>screening 1 week pre baseline visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>baseline visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>4 weeks post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>screening 1 week pre baseline visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>baseline visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>4 weeks post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>screening 1 week pre baseline visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>baseline visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>4 weeks post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CBC (complete blood count)</measure>
    <time_frame>screening 1 week pre baseline visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CBC (complete blood count)</measure>
    <time_frame>4 weeks post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid Panel</measure>
    <time_frame>screening 1 week pre baseline visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid Panel</measure>
    <time_frame>4 weeks post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c (glycated hemoglobin)</measure>
    <time_frame>screening 1 week pre baseline visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c (glycated hemoglobin)</measure>
    <time_frame>4 weeks post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CMP (comprehensive metabolic panel)</measure>
    <time_frame>screening 1 week pre baseline visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CMP (comprehensive metabolic panel)</measure>
    <time_frame>4 weeks post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma hsCRP (high-sensitivity C-reactive protein)</measure>
    <time_frame>screening 1 week pre baseline visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma hsCRP (high-sensitivity C-reactive protein)</measure>
    <time_frame>4 weeks post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma IL-6 (inflammatory biomarker)</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma IL-6 (inflammatory biomarker)</measure>
    <time_frame>4 weeks post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma IL-6R (inflammatory biomarker)</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma IL-6R (inflammatory biomarker)</measure>
    <time_frame>4 weeks post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PASP biomarkers (inflammatory biomarkers)</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PASP biomarkers (inflammatory biomarkers)</measure>
    <time_frame>4 weeks post baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>p16INK4a biomarker (inflammatory biomarker)</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>p16INK4a biomarker (inflammatory biomarker)</measure>
    <time_frame>4 weeks post baseline</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis (IPF)</condition>
  <arm_group>
    <arm_group_label>Dasatinib + Quercetin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib + Quercetin</intervention_name>
    <arm_group_label>Dasatinib + Quercetin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men between ages 50 and above, at the time of signing the informed consent.

          2. Post-menopausal women ages 50 and above, at the time of signing the informed consent.
             Note: Postmenopausal is defined as 12 months of spontaneous amenorrhea determined by
             self-report.

          3. A clinical diagnosis of IPF and characteristic chest HRCT scan (determined by panel of
             pulmonary radiologists) OR biopsy showing usual interstitial pneumonia (UIP).

          4. Body Mass Index (BMI) within the range 19 - 39.9 kg/ m2 (inclusive), where BMI =
             (weight in kg) / (height in meters)2 .

          5. Subjects participating in an exercise program must be willing to maintain their
             current activity level for the duration of the study period.

          6. Patients on stable therapy with nintedanib (Ofev) or pirfenidone (Esbriet) over the
             past 3 months.ORPatients not taking nintedanib (Ofev) or pirfenidone (Esbriet) may be
             enrolled if they have previously not tolerated one of those medications or if those
             medications have not yet been prescribed or used by the patient.

          7. Giving signed informed consent.

          8. No plans to travel over the next 6 weeks.

        Exclusion Criteria:

          1. More than two moderate/severe IPF exacerbations within the past year Exacerbation is
             defined as worsening of two or more of the following major symptoms: dyspnea, sputum
             volume, sputum purulence OR worsening of any one major symptom together with at least
             one of the following additional symptoms: sore throat, colds (nasal discharge and/or
             nasal congestion), fever &gt; 37.5 Â° C without any explained cause, increased cough,
             increase wheeze.

             A moderate exacerbation is defined as an event that is associated with a new
             prescription for antibiotics and/or oral steroids. A severe exacerbation is defined as
             an event that is associated with hospitalization or emergency room visit.

          2. Any moderate/severe IPF exacerbation within the past 4 weeks.

          3. History of a lung transplant.

          4. Use of anti-arrhythmic medications known to cause QTc prolongation.

          5. Pulmonary hypertension or cor pulmonale confirmed by echocardiography or heart
             catheterization.

          6. Myocardial infarction, angina, hospitalization for cardiac aetiology, stroke or
             transient ischemic attack in the past 6 months.

          7. Chronic heart failure.

          8. Neurologic, musculoskeletal, or other condition that in the opinion of the study
             physician limits subject's ability to complete study physical assessments.

          9. Uncontrolled diabetes (HbA1c &gt; 8% and fasting glucose &gt;200 mg/dL or the current use of
             insulin).

         10. Subjects with values outside the specified ranges for the following Key Clinical
             Laboratory Tests must be excluded from the study:

             Renal function: Glomerular Filtration Rate (GFR) &lt;30 (mL/min/1.73 m2) using formulae
             provided in the Study Reference Manual (SRM). Note: Subjects receiving dialysis are
             excluded from this study.

             ALT &gt;2xULN and bilirubin &gt;1.5xULN (isolated bilirubin &gt;1.5xULN is acceptable if
             bilirubin is fractionated and direct bilirubin &lt;35%).

         11. Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

         12. QTcB or QTcF &gt; 450 msec or QTc &gt; 480 msec in subjects with Bundle Branch Block based
             on a single ECG.

         13. Subjects with a history of malignancy that is not in complete remission for at least 2
             years or 1 year for non-melanoma skin carcinoma.

         14. The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to participation in the current study:
             30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

         15. History of drug or alcohol abuse within 5 years prior to randomization.

         16. Use of Coumadin or other anti-platelet or anti-coagulant medication. The use of
             aspirin is permitted.

         17. Current use of quinolone antibiotics.

         18. Low CBC.

         19. Cognitive Impairment (MoCA score less than 21)

         20. Other medical or behavioral factors that in the judgment of the principal investigator
             may interfere with study participation or the ability to follow the intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Kritchevsky, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest Univerisity Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02874989/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

